Skip to main content
Journal cover image

Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes.

Journal articles  - Journal Article
Boeckh, M; Xie, H; Stevens-Ayers, T; Sircy, L; Zamora, D; Goldman, JD; Woods, CW; Stapleton, RD; Rubenfeld, G; Kalil, A; Jerome, KR ...
Published in: J Infect Dis
May 15, 2026

BACKGROUND: Cytomegalovirus (CMV) reactivation occurs in the context of coronavirus disease 2019 (COVID-19); however, the viral kinetics, risk factors, and clinical outcomes are poorly defined. METHODS: We examined the association of CMV DNAemia with clinical outcomes among participants of a randomized trial of remdesivir with or without baricitinib (National Institute of Allergy and Infectious Diseases [NIAID], Adaptive COVID-19 Treatment Trial 2 [ACTT-2]). Plasma CMV DNAemia from CMV-seropositive participants with COVID-19 (NIAID ordinal scale [OS] 5, 6, or 7 at entry) were assessed longitudinally by quantitative polymerase chain reaction. Factors associated with CMV DNAemia, and clinical outcomes were analyzed by Cox regression and proportional odds models. RESULTS: Of 772 trial participants with available samples, 643 (83%) were CMV seropositive. Baseline CMV serostatus was not associated with COVID-19 outcomes. The cumulative incidence of CMV DNAemia among seropositive persons by day 28 was overall 11% (baseline OS 5, 6.3%; OS 6, 16.4%; OS 7, 24.7%), and was associated with older age, baseline OS, male sex, lymphopenia, and systemic corticosteroid use, while remdesivir and baricitinib did not affect risk. CMV DNAemia was associated with a lower probability of improvement by day 29 (adjusted hazard ratio, 0.3 [95% confidence interval, .17-.56]), with a more pronounced delay of recovery with higher CMV viral load. CMV DNAemia was also associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load and death. CONCLUSIONS: In hospitalized adults with COVID-19 requiring oxygen, CMV viremia occurs within well-defined clinical risks and is independently associated with delayed recovery from illness, higher SARS-CoV-2 viral load, and increased mortality.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Infect Dis

DOI

EISSN

1537-6613

Publication Date

May 15, 2026

Volume

233

Issue

5

Start / End Page

812 / 822

Location

United States

Related Subject Headings

  • Viremia
  • Viral Load
  • Treatment Outcome
  • Sulfonamides
  • SARS-CoV-2
  • Risk Factors
  • Pyrazoles
  • Purines
  • Oxygen Inhalation Therapy
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Boeckh, M., Xie, H., Stevens-Ayers, T., Sircy, L., Zamora, D., Goldman, J. D., … Limaye, A. P. (2026). Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes. J Infect Dis, 233(5), 812–822. https://doi.org/10.1093/infdis/jiaf649
Boeckh, Michael, Hu Xie, Terry Stevens-Ayers, Linda Sircy, Danniel Zamora, Jason D. Goldman, Christopher W. Woods, et al. “Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes.J Infect Dis 233, no. 5 (May 15, 2026): 812–22. https://doi.org/10.1093/infdis/jiaf649.
Boeckh, Michael, et al. “Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes.J Infect Dis, vol. 233, no. 5, May 2026, pp. 812–22. Pubmed, doi:10.1093/infdis/jiaf649.
Boeckh M, Xie H, Stevens-Ayers T, Sircy L, Zamora D, Goldman JD, Woods CW, Stapleton RD, Rubenfeld G, Kalil A, Jerome KR, Dasgupta S, Limaye AP. Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes. J Infect Dis. 2026 May 15;233(5):812–822.
Journal cover image

Published In

J Infect Dis

DOI

EISSN

1537-6613

Publication Date

May 15, 2026

Volume

233

Issue

5

Start / End Page

812 / 822

Location

United States

Related Subject Headings

  • Viremia
  • Viral Load
  • Treatment Outcome
  • Sulfonamides
  • SARS-CoV-2
  • Risk Factors
  • Pyrazoles
  • Purines
  • Oxygen Inhalation Therapy
  • Middle Aged